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A B S T R A C T 
Introduction: Malignant pleural effusion can be 
recurrent despite active anti-cancer treatment. 
Significant malignant pleural effusion leads to 
debilitating dyspnoea and worsening quality of life in 
patients with advanced cancer. An indwelling pleural 
catheter offers a novel means to manage recurrent 
malignant pleural effusion and may remove the 
need for repeated thoracocentesis. Spontaneous 
pleurodesis is another unique advantage of 
indwelling pleural catheter placement but the 
factors associated with its occurrence are not clearly 
established. The aims of this study were to explore 
the safety of an indwelling pleural catheter in the 
management of symptomatic recurrent malignant 
pleural effusion, and to identify the factors associated 
with spontaneous pleurodesis.
Methods: This case series with internal comparisons 
was conducted in the Division of Respiratory 
Medicine, Department of Medicine, Queen Mary 
Hospital, Hong Kong. All patients who underwent 
insertion of an indwelling pleural catheter from 
the initiation of such service from January 2010 to 
December 2014 were included for data analysis. 
Patients were monitored until December 2014, with 
the last catheter inserted in July 2014. 
Results: Between 2010 and 2014, a total of 23 
indwelling pleural catheters were inserted in 22 
consecutive patients with malignant pleural effusion, 
including 15 (65.2%) cases with malignant pleural 
Managing malignant pleural effusion with an 
indwelling pleural catheter: factors associated 
with spontaneous pleurodesis
Introduction
Malignant pleural effusion (MPE) develops in up 
to 50% of patients with advanced lung cancer1 and 
can also develop in metastatic pleural involvement 
from non-pulmonary cancers. Such complication 
can be recurrent despite active anti-cancer 
treatment and thus difficult to manage.1 Significant 
New knowledge added by this study
• An indwelling pleural catheter (IPC) offers a new and safe management option for symptomatic malignant 
pleural effusion (MPE).
• Potential clinical factors associated with spontaneous pleurodesis were identified.  
Implications for clinical practice or policy
• IPC is a safe management option for MPE.
• In addition to drainage of effusion, the use of an IPC may be followed by spontaneous pleurodesis that obviates 
the need for any additional chemical sclerosant.
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MPE leads to debilitating dyspnoea and worsening 
quality of life in patients with terminal cancer.2 
Conventional management options of MPE include 
thoracocentesis, chest tube drainage, and chemical 
and surgical pleurodesis.3 Nonetheless, MPE often 
recurs and necessitates repeated thoracocentesis 
or chest tube drainage.4 Chemical pleurodesis via 
ORIGINAL ARTICLE
effusion as a result of metastatic lung cancer. Ten 
(43.5%) cases achieved minimal output according to 
defined criteria, in five of whom the pleural catheter 
was removed without subsequent re-accumulation 
of effusion (ie spontaneous pleurodesis). Factors 
associated with minimal output were the absence 
of trapped lung (P=0.036), shorter time from first 
appearance of malignant pleural effusion to catheter 
insertion (P=0.017), and longer time from catheter 
insertion till patient’s death or end of study (P=0.007).
Conclusions: An indwelling pleural catheter 
provides a safe means to manage symptomatic 
malignant pleural effusion. Potential clinical factors 
associated with minimal output were identified along 
with the occurrence of spontaneous pleurodesis, 
which is a unique advantage offered by indwelling 
pleural catheter. 
#  Malignant pleural effusion  # 
335Hong Kong Med J  ⎥  Volume 22 Number 4  ⎥  August 2016  ⎥  www.hkmj.org
持續胸腔引流治理惡性胸腔積液：與自發性胸膜
固定相關的因素
黃慰梅、譚子雋、黃敬恩、雷美詩、葉秀文、林志良
引言：儘管積極進行抗癌治療，惡性胸腔積液的情況仍會復發。惡性
胸腔積液會導致晚期癌症患者呼吸困難，使其生活質量下降。持續胸
腔引流（IPC）為惡性胸腔積液提供一種嶄新的治理方法，並可能減
低重複胸腔穿刺的需要。IPC有可能引致自發性胸膜固定，這亦是引
流的另一項優勢，可惜自發性胸膜固定出現的因素尚未確定。本研究
探討IPC治理有症狀的惡性胸腔積液的安全性，並找出與自發性胸膜
固定相關的因素。
方法：這個具群組內部比較的病例系列在香港瑪麗醫院的呼吸內科部
進行。我們於2010年1月開始引入IPC的技術。本研究把2010年1月至
2014年12月期間所有接受IPC的病人列入研究範圍；研究期間的最後
一次IPC於2014年7月進行，病人數據更新至2014年12月。
結果：2010年至2014年間共有23例（22名病人）IPC，其中15例
（65.2%）因肺癌轉移出現惡性胸腔積液。根據治療準則，10例
（43.5%）達到最小輸出，其中5例被移除導管而沒有積液（即自發性
胸膜固定）。與最小輸出有關的因素包括：沒有萎陷肺（P=0.036）、
從發現惡性胸腔積液至導管插入的時間較短（P=0.017），以及從導
管插入至病人死亡或研究結束的時間較長（P=0.007）。
結論：使用IPC治理有症狀的惡性胸腔積液是安全的。本研究找出與
最小輸出和自發性胸膜固定（IPC的一項獨特優勢）有關的潛在臨床
因素。
an intercostal chest tube may entail prolonged 
hospitalisation and despite initial ‘success’, MPE 
often recurs a few months later.5 Surgical pleurodesis 
is often too invasive for frail cancer patients.6 
Systemic anti-cancer treatment may reduce MPE but 
there is no guarantee of success.7 To secure symptom 
relief and to minimise repeated interventions and 
hospitalisation in refractory MPE was a constant 
challenge, until an indwelling pleural catheter (IPC) 
became more commonly used.8
 An IPC is intended to be left in situ in the 
pleural cavity permanently in patients with advanced 
cancer. Insertion is under local anaesthesia, and 
supplemented with conscious sedation if needed. 
An IPC is a silicon catheter with a polyester cuff for 
anchoring the catheter at the subcutaneous tunnel 
that serves to reduce infection. At the end of the 
external portion of the catheter is a silicone valve 
that remains closed unless connected to a designated 
drainage line or vacuum bottle. Vacuum bottles are 
not reusable and are discarded after each episode of 
drainage. Patients are usually advised to have IPC 
drainage every 1 or 2 days, especially when output 
remains substantial. In addition, drainage should be 
done whenever symptoms of MPE occur (Fig).
 The guidelines for management of MPE 
published by the British Thoracic Society suggest 
FIG.  (a) An indwelling pleural catheter (IPC) kit (Rocket Medical, UK). 
(b) Connecting different parts of IPC. (c) IPC inserted in a patient
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that IPC is an alternative option for patients whose 
estimated survival exceeds 1 month and who have 
either a trapped lung or recurrent pleural effusion 
following a trial of pleurodesis.3 First-line use of IPC 
in patients who have no previous trial of pleurodesis 
has also been shown to be superior to talc pleurodesis 
with subjects being less dyspnoeic at 6 months, 
and less likely to need further pleural procedures, 
and reduced hospital stay by 3.5 days.9 Another 
prospective open-label trial that compared IPC with 
talc slurry pleurodesis as first-line treatment for MPE 
also demonstrated that first-line use of IPC conferred 
non-inferior improvement in dyspnoea and quality 
of life, reduced effusion-related hospital stay by 
7 to 11 days, and required less subsequent pleural 
procedures compared with talc slurry pleurodesis.10 
Research has shown that IPC is a safe procedure, 
with no complications in 87.5% (range, 54.5-100%) 
of patients.11 Although the IPC is designed to be left 
permanently in situ in the pleural cavity in patients 
with advanced cancer, one unique advantage of IPC 
is the occurrence of autopleurodesis or spontaneous 
pleurodesis (SP)—ie pleurodesis achieved following 
IPC insertion without the use of sclerosant. The 
achievement of SP may enable consequent removal 
of the IPC. The pooled rate of SP in MPE patients has 
been reported to be 45.6%,11 achieved after a mean 
duration of 26 to 56 days after IPC insertion.11-20 The 
possibility of SP is attractive as there is a chance that 
an IPC will no longer be required. The aims of this 
study were to review our single-centre experience of 
the safety of IPC in the management of symptomatic 
MPE and to explore the potential clinical factors 
associated with SP. To our knowledge, this is the first 
IPC study published in Hong Kong.
Methods
All patients who underwent IPC insertion at the 
Division of Respiratory Medicine, Department of 
Medicine, Queen Mary Hospital since initiation of 
the IPC service in January 2010 up to December 2014 
were included for data analysis. Patients and data 
were followed up until December 2014, with the last 
IPC inserted in July 2014. The study was approved by 
the University of Hong Kong/Hong Kong Hospital 
Authority Hong Kong West Cluster Institutional 
Review Board/Ethics Committee (HKU/HAHO 
HKWC IRB/EC UW13-581) and informed consent 
was obtained from patients. 
 An IPC was inserted in patients with MPE 
who had trapped lung or prior failed pleurodesis or 
persistent high effusion output from a chest drain 
and a high chance of pleurodesis failure, or in patients 
who preferred IPC as their first-line management of 
MPE. The IPC kits (Rocket Medical, UK) were used 
and IPCs were inserted in the endoscopy room under 
local anaesthesia supplemented with conscious 
sedation if needed. 
 The electronic patient records, in-patient 
records, chest radiographs, and drainage diaries 
were retrospectively reviewed. Data regarding 
patient demographics, primary malignancy, cancer 
treatment, history of thoracic irradiation, number 
and type of prior pleural procedures, indications 
for IPC, serum albumin level before IPC insertion, 
laboratory analysis of pleural fluid obtained prior to 
IPC insertion, and IPC-related complications and 
admissions were collected and evaluated. ‘Massive 
effusion’ was defined as more than two thirds of the 
hemithorax. Effusion less than or equal to two thirds 
of the hemithorax was defined as ‘non-massive 
effusion’. Trapped lung was clinically diagnosed when 
chest X-ray showed an incompletely re-expanded 
lung despite adequate drainage and suction, together 
with a compatible tumour status predisposing 
to trapped lung (eg endobronchial tumour). The 
number of IPCs inserted, instead of the number of 
patients, was used for analysis in this study unless 
otherwise specified.
 Although IPC removal could be considered 
when SP was achieved clinically, there were patients 
who achieved minimal IPC output in whom IPC was 
not removed due to other clinical considerations 
or patient preference. Hence, the rate of SP would 
be underestimated if only IPC removal of the basis 
of minimal output was considered to reflect SP. 
Therefore, in this study patients were deemed to have 
achieved ‘minimal output’ if there was a persistently 
reduced IPC output of ≤50 mL per day on average 
that was not secondary to IPC complications, and 
regardless of whether the IPC was removed or kept 
in situ. Patients who persistently had an average 
IPC output that exceeded 50 mL per day, or had 
little output due to IPC complications (eg blocked 
IPC or significant pleural loculation) were defined 
as the ‘persistent output’ group. As achievement of 
SP did not necessarily infer IPC removal, because of 
patient preference and/or other considerations, the 
endpoint ‘minimal output’ was used for analysis of 
factors associated with SP. 
 The IBM PASW statistical software version 20 
was used for data analysis. Association of clinical 
factors with outcome was analysed with Fisher’s 
exact test, independent sample t tests, and Mann-
Whitney test where appropriate. Shapiro-Wilk 
tests were used to check for normal distribution of 
individual continuous variables. As minimal output 
was a dichotomous variable, the point-biserial 
correlation method was used for association analysis 
between minimal output and other factors that were 
continuous variables. The P values were two-sided 
and were considered statistically significant if <0.05.
Results
A total of 23 IPCs were inserted in 22 consecutive 
patients with symptomatic MPE. Insertion of 15 
#  Malignant pleural effusion  # 
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(65.2%) IPCs were in patients with MPE from 
metastatic lung cancer. A further six were inserted 
for MPE from metastatic breast cancer and two in 
patients with MPE from metastatic colon cancer. 
The characteristics of patients are shown in Table 1. 
The mean (± standard error of the mean) duration of 
follow-up was 33.3 ± 28.1 weeks.
 Patients were admitted for symptomatic MPE 
or elective IPC insertion. Patients were able to be 
discharged with a mean of 4 days following IPC 
insertion. Ambulatory IPC drainage via vacuum 
bottles was performed by patients and/or their 
carers, except one patient who was attended by 
outreach nurses of the palliative care team. 
 Complications related to IPC occurred in 10 
(43.5%) cases (Table 2). Site infection and wound 
infection following IPC removal were minor and all 
resolved after a course of oral antibiotics without 
the need for hospitalisation. Tumour seeding at 
the IPC tract was successfully treated by local 
radiotherapy. Two patients had symptomatic 
loculated effusion following IPC insertion and 
required intrapleural fibrinolytics: only one of them 
improved. Complications necessitated removal of 
two IPCs. One patient developed empyema 6 months 
after IPC insertion. Pseudomonas aeruginosa was 
persistently isolated from pleural fluid despite 
appropriate antibiotics; infection resolved following 
IPC removal. Another patient developed intractable 
cough and it was suspected that her IPC was trapped 
at the right oblique fissure causing irritation. Cough 
improved following IPC removal. There were six 
IPC complication–related hospitalisations (either 
clinical or emergency admissions) in three patients: 
the two patients with symptomatic loculations on 
the IPC requiring fibrinolytics and the patient with 
empyema mentioned above.
 A total of 10 patients achieved minimal output: 
IPC was removed in five (21.7%) without subsequent 
effusion re-accumulation and the other five patients 
achieved minimal output but retained their IPC. In 
another two patients, IPC was removed because of 
complications as mentioned before. No difficulties 
were encountered during any IPC removal. 
 Significant factors associated with minimal 
output were the absence of trapped lung (P=0.036), 
shorter time from first appearance of MPE to IPC 
insertion (24.5 ± 24.2 weeks in persistent output 
group vs 5.75 ± 4.91 weeks in minimal output group; 
P=0.017), and longer time from IPC insertion till 
patient’s death or end of study (whichever was earlier; 
20.2 ± 19.5 weeks in persistent output group vs 50.3 
± 29.2 weeks in minimal output group; P=0.007; 
Table 3).
Discussion
In this small series of 22 patients with 23 IPCs, 
mainly minor complications were encountered. 
A serious IPC complication, namely empyema, 
occurred in one (4.3%) case who was successfully 
treated with antibiotics and removal of IPC without 
serious consequences. Insertion of IPC is considered 
a relatively safe procedure: up to 87.5% (range, 54.5-
TABLE 1.  Summary of characteristics of subjects included in this study (n=23)
Characteristic Data*
Gender
Male 6 (26.1%)
Female 17 (73.9%)
Age (years) 59.3 ± 14.3
Smoking habit
NS 18 (78.3%)
Current/ex-smoker 5 (21.7%)
Cancer
Lung primary 15 (65.2%)
Non–lung primary 8 (34.8%)
Presence of trapped lung
No 12 (52.2%)
Yes 11 (47.8%)
Effective anti-cancer treatment on IPC
No treatment/PD 16 (69.6%)
PR/SD on treatment 7 (30.4%)
History of pleural tappings ≥2
No 8 (34.8%)
Yes 15 (65.2%)
History of pleurodesis
No 20 (87.0%)
Yes 3 (13.0%)
Pleural fluid cytology
Negative 5 (21.7%)
Positive 18 (78.3%)
Non-massive pleural effusion
Small-to-moderate initial MPE 5 (21.7%)
Massive initial MPE 18 (78.3%)
Drainage schedule† 20 (87.0%) 
Every 1-2 days 8 (34.8%)
>Every 2 days 12 (52.2%)
Duration from first appearance of MPE to IPC insertion (weeks) 16.4 ± 20.5
Duration from IPC insertion to hospital discharge (days) 4.4 ± 3.0
Duration from IPC insertion to IPC removal due to SP (weeks)‡ 19.0 ± 9.8
Duration from IPC insertion till death or end of study (weeks) 33.3 ± 28.1
Abbreviations: IPC = indwelling pleural catheter ; MPE = malignant pleural effusion; NS = 
non-smoker; PD = progressive disease; PR = partial response; SD = stable disease; SP = 
spontaneous pleurodesis
* Data are shown as No. (%) of insertions or mean ± standard error of the mean
†  Three patients did not keep drainage diary and hence drainage frequency not 
traceable
‡  No. of patients = 5 (21.7%) 
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100%) of patients have no complications following 
the insertion.11 Complications reported in the 
literature include local pain (0.4-13%), bleeding (0-
0.9%), pneumothorax (0-38%), cellulitis at exit site 
(1.3-25%), pleural infection (0-16.7%), asymptomatic 
loculations (4-7.3%), symptomatic loculations (2-
13.5%), IPC tract metastasis (0-13.6%), clogged 
catheter (0-17.6%), IPC dislodgement (1.3-
17.7%), and fractured IPC during removal (9.8%). 
Previous studies suggest that up to 20.6% (range, 
1.6-20.6%) of IPCs need to be removed due to 
complications.9-11,14,15,21,22 Nonetheless, serious 
complications are uncommon; the most common 
being pleural infection (0-16.7%).23 The TIME2 
study reported that the risk of pleural infection was 
13.4% in the IPC group compared with 1.9% in the 
talc slurry pleurodesis group.9 Chemotherapy is 
not regarded as a contra-indication to IPC, or vice 
versa. No increased risk of pleural infection has been 
observed in patients who receive chemotherapy with 
an IPC in situ.24 Symptomatic loculations following 
IPC insertion is another relatively significant 
complication, as they often necessitate admission 
for management such as intrapleural fibrinolysis or 
other pleural procedure. 
 When the daily IPC output reduces to a 
certain level (the exact ‘amount’ remains arbitrary), 
IPC removal can be considered and SP is achieved 
if there is no significant re-accumulation following 
IPC removal. In reality, some patients had little 
IPC output but the catheter was left in situ due to 
other clinical considerations. The rate of SP could 
be underestimated if it was solely reflected by the 
ultimate rate of IPC removal, hence ‘minimal output’ 
was used in this study as the surrogate of SP during 
analysis of factors that contributed to SP. 
 We determined that absence of trapped lung, 
shorter time from first appearance of MPE to IPC 
insertion, and longer time from IPC insertion till 
patient’s death or end of study were associated with 
minimal output. Trapped lung unsurprisingly led to 
a higher chance of persistent output. Nonetheless, it 
has been observed that patients with IPC inserted 
for trapped lung can still achieve SP,12,15,17,18,20 or 
their lung expansion will improve after IPC.17 In 
our cohort, two patients had their trapped lung re-
expanded after IPC insertion; one of whom had IPC 
removed successfully without re-accumulation of 
effusion. 
 It appears from this study that a shorter time 
from MPE to IPC insertion could be associated with 
the achievement of a minimal output state. This 
could imply that the earlier an IPC is inserted, the 
better chance of achieving minimal output or even 
SP. Both a history of multiple pleural procedures 
(which was arbitrarily defined in this study as 
requiring two or more episodes of pleurocentesis or 
chest drainage) and a history of failed pleurodesis 
were usually indicative of refractory or difficult-
to-manage MPE.25 It has never been ascertained 
whether earlier IPC insertion rather than repeated 
attempts at pleurocentesis or pleurodesis will 
Abbreviations: IPC = indwelling pleural catheter ; MPE = malignant pleural effusion
TABLE 2.  Complications related to indwelling pleural catheter (IPC) in this study (n=23)
TABLE 3.  Association of clinical factors with minimal output by bivariate analysis
Complication No. (%) of cases
IPC-related complication
Tumour seeding at IPC tract 1 (4.3)
Symptomatic loculated effusion after IPC 2 (8.7)
Undrained effusion due to malpositioned IPC 1 (4.3)
Pleural infection 1 (4.3)
IPC entry- or exit-site cellulitis 4 (17.4)
Infection at wound of IPC removal (n=7) 1
IPC-related hospitalisations Total of 6 admissions in 3 patients
IPC removal due to complications 2 (8.7%)
Clinical factor Point-biserial correlation coefficient P value
Duration of IPC from insertion to death or end of study 0.567 0.007
Trapped lung -0.472 0.036
Duration from first appearance of MPE to IPC insertion -0.473 0.017
#  Malignant pleural effusion  # 
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increase the chance of SP with IPC. Both factors were 
not significantly associated with minimal output in 
our small cohort. Further studies are required to 
investigate whether prompt insertion of IPC as soon 
as possible after development of MPE will improve 
the likelihood of  SP. 
 Patients who achieved minimal output had 
a longer time from IPC insertion until death or 
end of study (20.2 ± 19.5 weeks in the persistent 
output group vs 50.3 ± 29.2 weeks in the minimal 
output group; P=0.007). Minimal output may be 
a marker of overall disease control. Lung cancer 
was the underlying pathology in eight of the 10 
subjects who achieved minimal output, of whom 
six had adenocarcinoma and were prescribed 
targeted therapy and chemotherapy. Whether the 
concomitant use of anti-cancer treatments for these 
lung cancer patients contributed to longer survival 
following IPC insertion could not be established 
from this small cohort of lung cancer patients. 
Comparison with non–lung cancer patients with 
IPC in this study could not be made as patients with 
metastatic breast or colorectal tumour with MPE had 
different treatment strategies. As at December 2014, 
only four of the 22 patients were still living. They 
were patients with adenocarcinoma of the lung on 
palliative chemotherapy/tyrosine kinase inhibitors. 
Among these four patients, one had her IPC removed 
earlier due to SP achievement, two had IPC removed 
earlier due to IPC-related complications, and one 
still had IPC in situ with persistent output.
 Minimal output was used as a surrogate of SP 
in this study rather than actual IPC removal in the 
hope that it would better reflect what clinical factors 
contribute to SP. Comparison of time from IPC 
insertion to minimal output achievement in those 
five patients whose IPCs were ultimately removed 
and the five patients in whom IPC remained in 
situ despite minimal output revealed no significant 
difference (30 [interquartile range, 15-59] days 
vs 23 [standard error of the mean, 6.63] days). 
Nonetheless, one must not ignore the reasons for 
non-removal of IPC despite minimal output since 
they impact the ultimate goal of IPC removal. In this 
study, there were five patients who achieved minimal 
output but in whom IPCs remained in situ due to 
various reasons: poor performance state and short 
life expectancy, undergoing cycles of chemotherapy, 
or patient preferences. 
 This study was limited by the very small 
sample size and its retrospective nature. There were 
missing data and the dichotomous groupings, eg IPC 
drainage every 1 to 2 days versus less frequent, were 
crude and arbitrary. For example, more-frequent 
IPC drainage to increase the chance of pleural 
apposition may theoretically increase the chance of 
SP, although in this study IPC drainage every 1 to 
2 days versus less frequent was not associated with 
minimal output. This could be related to the crude 
grouping of the IPC drainage frequency due to the 
retrospective design of this study that did not allow 
us to properly allocate the IPC drainage schedule. 
Further studies to identify modifiable clinical 
factors that may facilitate SP would be particularly 
meaningful. 
Conclusions
Insertion of IPC was shown to be a safe technique 
in the management of symptomatic MPE. Potential 
factors associated with minimal output, which may 
predict SP, were absence of trapped lung, shorter time 
from first appearance of MPE to IPC insertion, and 
longer time with IPC. Validation by further studies 
is required owing to the small number of subjects 
in this study. More data are needed regarding 
modifiable factors that contribute to achievement of 
minimal output, as the removal of IPC offers further 
enhancement of quality of life. 
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